Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.

Hdl Handle:
http://hdl.handle.net/10147/94216
Title:
Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.
Authors:
Curran, Desmond; Pozzo, Carmelo; Zaluski, Jerzy; Dank, Magdalena; Barone, Carlo; Valvere, Vahur; Yalcin, Suayib; Peschel, Christian; Wenczl, Miklós; Goker, Erdem; Bugat, Roland
Affiliation:
Omega Research, Santry, Dublin 9, Ireland. currandes@omega-research.eu.com
Citation:
Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial. 2009, 18 (7):853-61 Qual Life Res
Journal:
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
Issue Date:
Sep-2009
URI:
http://hdl.handle.net/10147/94216
DOI:
10.1007/s11136-009-9493-z
PubMed ID:
19568958
Abstract:
PURPOSE: The quality of life (QL) of advanced gastric cancer patients receiving irinotecan, folinic acid and 5-fluorouracil (5-FU) (IF arm) or cisplatin with 5-FU (CF arm) is presented. METHODS: Patients with measurable or evaluable advanced gastric cancer received IF weekly for 6/7 weeks or CF q4 weeks. QL was assessed using the EORTC QLQ-C30 at baseline, subsequently every 8 weeks until progression and thereafter every 3 months until death. The QL data were analysed using several statistical methods including summary measures and pattern-mixture modelling. RESULTS: A total of 333 patients were randomised and treated (IF 170, CF 163). The time-to-progression for IF and CF was 5.0 and 4.2 months (P = 0.088), respectively. The overall compliance rates for QL questionnaire completion were 60 and 56% in the IF and CF arms, respectively. Significant treatment differences were observed for the physical functioning scale (P = 0.024), nausea\vomiting (P = 0.001) and EQ-5D thermometer (P = 0.020) in favour of the IF treatment arm. CONCLUSION: There was a trend in favour of IF over CF in time-to-progression. The IF group also demonstrated a better safety profile than CF and a better QL on a number of multi-item scales, suggesting that IF offers an alternative first-line platinum-free treatment option for advanced gastric cancer.
Language:
en
MeSH:
Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Esophagogastric Junction; Fluorouracil; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Palliative Care; Quality of Life; Stomach Neoplasms; Young Adult
ISSN:
1573-2649

Full metadata record

DC FieldValue Language
dc.contributor.authorCurran, Desmonden
dc.contributor.authorPozzo, Carmeloen
dc.contributor.authorZaluski, Jerzyen
dc.contributor.authorDank, Magdalenaen
dc.contributor.authorBarone, Carloen
dc.contributor.authorValvere, Vahuren
dc.contributor.authorYalcin, Suayiben
dc.contributor.authorPeschel, Christianen
dc.contributor.authorWenczl, Miklósen
dc.contributor.authorGoker, Erdemen
dc.contributor.authorBugat, Rolanden
dc.date.accessioned2010-03-12T15:41:25Z-
dc.date.available2010-03-12T15:41:25Z-
dc.date.issued2009-09-
dc.identifier.citationQuality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial. 2009, 18 (7):853-61 Qual Life Resen
dc.identifier.issn1573-2649-
dc.identifier.pmid19568958-
dc.identifier.doi10.1007/s11136-009-9493-z-
dc.identifier.urihttp://hdl.handle.net/10147/94216-
dc.description.abstractPURPOSE: The quality of life (QL) of advanced gastric cancer patients receiving irinotecan, folinic acid and 5-fluorouracil (5-FU) (IF arm) or cisplatin with 5-FU (CF arm) is presented. METHODS: Patients with measurable or evaluable advanced gastric cancer received IF weekly for 6/7 weeks or CF q4 weeks. QL was assessed using the EORTC QLQ-C30 at baseline, subsequently every 8 weeks until progression and thereafter every 3 months until death. The QL data were analysed using several statistical methods including summary measures and pattern-mixture modelling. RESULTS: A total of 333 patients were randomised and treated (IF 170, CF 163). The time-to-progression for IF and CF was 5.0 and 4.2 months (P = 0.088), respectively. The overall compliance rates for QL questionnaire completion were 60 and 56% in the IF and CF arms, respectively. Significant treatment differences were observed for the physical functioning scale (P = 0.024), nausea\vomiting (P = 0.001) and EQ-5D thermometer (P = 0.020) in favour of the IF treatment arm. CONCLUSION: There was a trend in favour of IF over CF in time-to-progression. The IF group also demonstrated a better safety profile than CF and a better QL on a number of multi-item scales, suggesting that IF offers an alternative first-line platinum-free treatment option for advanced gastric cancer.-
dc.language.isoenen
dc.subject.meshAdenocarcinoma-
dc.subject.meshAdolescent-
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCamptothecin-
dc.subject.meshCisplatin-
dc.subject.meshEsophagogastric Junction-
dc.subject.meshFluorouracil-
dc.subject.meshHumans-
dc.subject.meshLeucovorin-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Metastasis-
dc.subject.meshPalliative Care-
dc.subject.meshQuality of Life-
dc.subject.meshStomach Neoplasms-
dc.subject.meshYoung Adult-
dc.titleQuality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.en
dc.contributor.departmentOmega Research, Santry, Dublin 9, Ireland. currandes@omega-research.eu.comen
dc.identifier.journalQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitationen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.